Effect of Vitamin D₃ and Virgin Coconut Oil on Cartilage Degeneration, Inflammation and Functional Abilities in Early Knee Osteoarthritis

Monal Velangi¹, Subhadra Mandalika², Surendra Shukla³, Vandana Pradhan⁴

¹Department of Foods, Nutrition and Dietetics, College of Home Science, Nirmala Niketan, Affiliated to the University of Mumbai, Mumbai, 400020, India; ²College of Home Science, Nirmala Niketan, Affiliated to the University of Mumbai, 400020, India; ³Department of Orthopaedics, K. J. Somaiya Medical College, Hospital and Research Centre, Mumbai, 400022, India; ⁴Department of Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, 400012, India.

Corresponding Author: Monal Velangi, Ph.D., Department of Foods, Nutrition and Dietetics, College of Home Science, Nirmala Niketan, affiliated to the University of Mumbai, India; Department of Nutrition and Dietetics, K. J. Somaiya, Hospital and Research Centre, Sion, Mumbai, India.

Submission Date: August 26th, 2019 Acceptance Date: October 28th, 2019. Publication Date: October 30th, 2019

Citation: Velangi M, Mandalika S, Shukla S, Pradhan V: Effect of vitamin D₃ and virgin coconut oil on cartilage inflammation and functional abilities in early knee osteoarthritis. Functional Foods in Health and Disease 2019; 9(10): 662-677. DOI: https://doi.org/10.31989/ffhd.v9i10.653

ABSTRACT

Background: Knee osteoarthritis (KOA) is a chronic, degenerative knee joint disorder associated with inflammation, pain, stiffness, and reduced functional abilities, thereby impacting the patient’s quality of life. The prevalence of KOA is growing rapidly in India and around the globe, even in younger populations. Vitamin D plays a crucial role in musculoskeletal health and deficiency of this vitamin is highly prevalent across the age groups impacted by KOA. Consumption of vitamin D rich foods along with functional foods possessing antioxidant and analgesic properties needs to be explored as a potentially novel, low cost dietary strategy for the prevention and management of chronic musculoskeletal disorders such as KOA.

Objective: To assess the effect of vitamin D₃ and Virgin Coconut Oil (VCNO) supplementation on vitamin D₃ status, cartilage degeneration, inflammatory status, and functional abilities in early KOA.

Methods: One hundred vitamin D deficient, age and gender-matched adults afflicted by early KOA (30-65yrs) were selected purposively from K. J. Somaiya Hospital and Research Centre, Mumbai, India after obtaining ethical clearance from the institute. Informed consent was obtained...
from the participants. They were then counselled on making required dietary modifications, with due emphasis on vitamin D3 rich foods, and were given an at-home KOA exercise program. The participants were divided equally into two experimental groups: E1 (n=50) and E2 (n=50), with equal number of males and females in each group. The groups were either supplemented with Vitamin D3 alone (group E1) or Vitamin D3 + VCNO (group E2). All the participants were assessed for vitamin D status (serum 25 (OH) D levels (CLIA), Vitamin D3 intake (3-day diet recall and FFQ), pain (VAS), stiffness, functional abilities (WOMAC and 6 MWT), and inflammation (ESR and serum CRP). The cartilage marker (s-COMP (ELISA)) was assessed only in a subset of participants (n =40) from each group, both pre and post intervention. Data were analyzed using SPSS 16.0.

Results: A significant rise in Vitamin D3 intake and serum vitamin D3 levels (p<.001) was observed post-supplementation in both groups. sCOMP (<.001), ESR, and serum CRP (<.001) were significantly reduced in both the groups, indicating a decline in cartilage degeneration and inflammatory status. VAS score (<.001) was significantly reduced in both groups, indicating reduced pain intensity. Total WOMAC score (p<.001) was significantly reduced, with a highly significant improvement in the distance covered during the 6 MWT (<.001), indicating improved functional abilities. The mean difference of effect in all the above parameters was higher in the vitamin D3 and VCNO supplementation group (E2) than the group which received vitamin D3 alone (E1).

Conclusion: Supplementation of vitamin D3 along with VCNO could be an effective strategy for delaying the progression of KOA by reducing cartilage degeneration, inflammation and pain, as well as improving functional abilities. Thus, simultaneous improvement of vitamin D3 status and oxidative stress should be considered in early KOA management. Non-conventional antioxidant and anti-inflammatory functional foods such as VCNO could be further explored.

Key words: Knee osteoarthritis, vitamin D, virgin coconut oil, anti-inflammatory, functional food, functional abilities, cartilage degeneration, inflammation, WOMAC, sCOMP.

INTRODUCTION

OA is a chronic degenerative joint disease characterized by cartilage degeneration, inflammation, and functional disability. Common symptoms are pain and stiffness which often impact a patient’s quality of life [1, 2]. It occurs in the joints of the hands, spine, hips, and knees. Knee osteoarthritis (KOA) prevalence is growing rapidly in India (28.7%) and around the globe in both urban and rural areas. Its incidence is currently higher in women than in men and a rising trend has been observed in younger populations. This change can have a tremendous impact on the functional capacity and productivity of these groups [5]. Progressive KOA shows an increase in bone resorption similar to osteoporosis [6]. Early stages of KOA can be managed by diet and exercise, however, advanced stages require surgical treatment. Appropriate dietary and exercise strategies are low cost, non-pharmacological interventions that could reduce cartilage degeneration and inflammation. Thus the anti-inflammatory and anti-oxidative roles of traditional functional foods need to be explored as a novel approach to the management of chronic musculoskeletal disorders.
Moreover, deficiency of Vitamin D is highly prevalent across the age groups impacted by KOA in India and globally [7, 8]. This indicates a strong need for further research on the role of vitamin D in the management of KOA [9]. Vitamin D contributes to joint health as an anti-inflammatory agent and if oxidative stress were to be controlled simultaneously, patients would likely encounter greater relief from the symptoms of degenerative diseases like KOA. There is a paucity of data on the definitive role of nutrition, specifically the impact of vitamin D and antioxidants, in minimizing osteoarthritis symptoms, thus necessitating evidence-based research [10]. Virgin coconut oil (VCNO) is an emerging functional food that has shown antioxidant effects in rats and which promotes osteoblastic activity, reducing bone resorption [11]. Most VCNO studies are on animal models and hence need to be scaled up to human research. In humans, VCNO could also have anti-inflammatory effects and facilitate the absorption of vitamin D in the gut if consumed simultaneously. Hence its role in the management of degenerative bone diseases such as KOA could be further explored. This study was conducted to understand the "Effect of vitamin D3 and Virgin Coconut oil on cartilage degeneration, inflammatory status, and functional abilities in early knee osteoarthritis." The investigators proposed the following null hypothesis: The intake of Vitamin D3 and VCNO does not offer any cumulative benefits to KOA patients.

**MATERIALS AND METHODS**

This research on the effect of Vitamin D3 and VCNO in early KOA, is an interventional, clinical trial approved by the Medical Ethics Committee of K.J. Somaiya Medical College, Hospital, and Research Centre, Mumbai, India.

**Place of the Study:** The study was conducted at the Department of Nutrition and Dietetics and the Department of Orthopaedics at K.J.Somaiya Hospital and Research Centre.

**Sampling:** One hundred vitamin D deficient (< 20 ng/ml) [12], age and gender-matched early KOA patients (30-65yrs) with symptoms of Kellgren Lawrence (KL) grades I and II [13] were diagnosed by an expert Orthopaedic surgeon and selected purposively from K.J. Somaiya Hospital and Research Centre, Mumbai, India. Pregnancy and lactation, history of arthroscopy, presence of other forms of arthritis, administration of intra-articular steroids within the past 3 months, administration of hyaluronic acid in the last 9 months, the presence of a simultaneous unstable disease (i.e. typhoid, malaria, tuberculosis, jaundice, tumor), cancer, severe renal or hematologic disorder, endocrine/hormonal disorders (thyroid and parathyroid but not diabetes mellitus), cardiac insufficiency, moderate to severe neuropathy, and spondylosis were the conditions considered for exclusion. The patients screened in the bone health camps who fit the inclusion-exclusion criteria were then made aware of the study and its potential benefits, and were given the opportunity to enroll. Those who voluntarily agreed to participate in the study were asked to sign an informed consent form.

**Research Design:** An experimental research design was planned to study the effect of the vitamin D3 and VCNO supplementation. The selected participants were divided equally into two experimental groups: Experimental Group 1 (E1) (n=50) and Experimental Group 2 (E2) (n=50), each with an equal number of males and females.
**Biochemical and Dietary Assessment:** A standardized questionnaire was used to record all the baseline data of the participants (sociodemographic information, physical assessment, biochemical assessment, diet history, sun exposure details, and functional abilities). All the participants were assessed for vitamin D status by the CLIA method using the ADVIA Centaur XP Vitamin D Total Assay, Immunoassay system (Siemens Healthcare, Erlangen, Germany) [14, 15]. Their vitamin D intake was assessed via a dietary history survey (3-day diet recall and food frequency questionnaire) [16]. Sun exposure data such as timing, duration, frequency, percent skin exposure, skin color, and clothing were also recorded [17, 18]. Other data were recorded such as self-perceived pain score via the visual analogue scale (VAS) [19], stiffness and functional abilities via the Western Ontario McMasters Osteoarthritis (WOMAC) Index [20] and a six minute walk test (6 MWT) [21], inflammation markers (Erythrocyte sedimentation rate, ESR) via the Westergren method [22], and serum C-reactive protein (CRP) via Rhelax slide test [23]. Serum cartilage oligomeric matrix protein (s-COMP), a novel prognostic biomarker and non-aggrecans marker of cartilage degeneration for early diagnosis of KOA patients [24], was analyzed at the National Institute of Immunohaematology (NIIH), ICMR, Mumbai, India, using the Human COMP ELISA Kit-EK0913 (Boster Bio, Fremont, California, USA) [25]. The standard reference values and cut-offs for the above methods are given below (Table 1).

**Table 1. Standard Reference Values and Cut-Offs of the Assessed Markers.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Markers</th>
<th>Standard Reference Values</th>
<th>Cut-offs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D&lt;sub&gt;3&lt;/sub&gt;</td>
<td>Serum 25 (OH) D (ng/ml)</td>
<td>30-70 #</td>
<td>&gt; 30</td>
</tr>
<tr>
<td>Pain score</td>
<td>VAS score (mm)</td>
<td>40-70*</td>
<td>&gt; 40</td>
</tr>
<tr>
<td>Functional abilities score</td>
<td>Total WOMAC score</td>
<td>0- 96*</td>
<td>≤ 59 (low) 60-80 (moderate) ≥ 81 (high)</td>
</tr>
<tr>
<td>Inflammatory markers</td>
<td>ESR (mm/hr)</td>
<td>0-20**</td>
<td>&lt; 20</td>
</tr>
<tr>
<td></td>
<td>Serum CRP (mg/dl)</td>
<td>0-2 **</td>
<td>&lt; 2.0</td>
</tr>
<tr>
<td>Cartilage biomarker (KOA prognostic biomarker)</td>
<td>sCOMP (pg/ml)</td>
<td>6000-7000***</td>
<td>&lt;6000</td>
</tr>
</tbody>
</table>

# Reference values and cut-offs for serum vitamin D levels, Institute of Medicine guidelines (2010) [12].  
* Reference values and cut-offs for VAS, Cut-off points for pain, Boonstra et al., in 2014 and Total WOMAC scores for early KOA (KL grades I and II) patients, www.rheumatology.com/WOMAC [19, 20].  
* Reference values and cut-offs for ESR and CRP levels, Westregren method, and Rhelax Slide test respectively [22, 23].  
**Reference values and cut-offs for sCOMP (Human COMP ELISA, Boster Bio, Fremont, USA) were established during this study at NIIH [24].

**Dietary and Exercise Modifications:** All the participants (n=100) were recommended dietary and exercise modifications with due consideration to their nutritional status and in accordance with ICMR guidelines (2010) [26], which include the management of obesity (small and frequent meals, and a balanced diet) as well as emphasis on the intake of bone micronutrients and anti-inflammatory foods (Table 2).
**Home Exercise Regimen for Early KOA:** Well-planned home exercise regimens have been reported to be effective in KOA management [27], hence a structured home-based KOA exercise program was advised for these participants. The program included a 3-4-minute warmup of gentle walking, followed by eight exercises: isometric quadriceps exercises, straight leg raise, static hold exercise, isometric hamstring exercise, knee flexion, knee extension, and hip abduction. For each exercise, participants were instructed to perform 10-15 repetitions, 2-3 times daily for the strengthening of quadriceps, hamstrings, vastus medialis, obliques, and tensor fascia lata muscles [28], and were asked to avoid cross legged sitting and squatting postures.

**Dietary Supplementation Protocols:** For the two experimental groups, the recommended supplementation protocols were intended for a period 12 weeks. Details of the implemented dietary supplementation protocols were as follows:

**Vitamin D3 Sources and Supplementation:** The dietary intake of Vitamin D3 was calculated using the recent Indian food data composition tables for vitamin D3 [29]. After considering the serum 25 (OH) D levels, dietary vitamin D3 consumption and sun exposure patterns of both groups, they were provided recommendations on modifying their consumption of vitamin D rich foods and on sun exposure. Additionally, they were supplemented with an injectable form of vitamin D, followed by weekly doses in powder form and daily doses in tablet form. Details of these dosages are given in Table 2.

**Table 2. Vitamin D3 Supplementation, Dietary and Sun Exposure Recommendations.**

<table>
<thead>
<tr>
<th>Duration (Weeks)</th>
<th>Form and dose of vitamin D3 supplementation as suggested by the expert Orthopedic Surgeon</th>
<th>Suggestions for Dietary Vitamin D3 and calcium intake and sun exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st week</td>
<td>One intramuscular injection of 600,000 IU</td>
<td>• Vitamin D3 rich foods: egg yolk, mackerel, sardines, salmon were suggested as per the dietary requirements to meet daily RDA of vitamin D.</td>
</tr>
<tr>
<td>2nd to 6th week</td>
<td>Oral supplements (powder) 60,000 IU Vitamin D3 sachet once a week for 5 weeks</td>
<td>• Calcium rich foods: milk, curd, Bombay duck, green leafy vegetables, dried prunes.</td>
</tr>
<tr>
<td>7th to 12th week</td>
<td>Oral supplements (tablet)–500 mg elemental calcium and 400 IU Vitamin D3 capsule daily</td>
<td>• Sun exposure: suggestion of direct sunlight exposure for 10-15 minutes between 11 am to 2 pm without sunscreen, with arms and face exposed.</td>
</tr>
</tbody>
</table>

# Note: Vitamin D3 and calcium rich foods list was adapted from Indian Food Composition tables (2017) and vitamin D3 requirements are in accordance with the RDA for Indians (2010) [29, 30]. The sun exposure window and duration mentioned in the table are in accordance with the geographic location of the tropical country, India [31].

**VCNO supplementation:** Group E2 received 2 teaspoons (i.e. 10 ml) of branded, FSSAI approved VCNO, which is 25% of the recommended allowance of daily visible dietary fat intake in
accordance with the RDA (2010) for Indian adults [30]. This dosage was administered twice daily during a regular meal, as a topping on the food consumed, (i.e. it was not involved in the cooking process) because exposure to high temperatures can cause the degradation of VCNO via oxidation. Participants (n=100) attended monthly follow-ups at the hospital. The follow-ups were planned to assess adherence to suggested diet and exercise changes along with providing reinforced counselling for diet and exercise.

**Post Intervention Reassessment:** After 12 weeks of supplementation, all the participants were reassessed for the various biochemical and functional markers mentioned above.

**Statistical Analysis:** The data were compiled into Microsoft Excel 2009 and analyzed using SPSS 16.0. A paired t-test was used to determine the effect of intervention on the selected parameters measured for the subjects of each experimental group. An independent sample t-test (unpaired t-test) was used to ascertain which of the 2 supplementation regimens was more effective in altering the selected parameters of early KOA management.

**RESULTS**

The results obtained after statistical analysis of the collected data are presented in the form of tables and graphical figures. To understand the effect of supplementation, the pre-post supplementation data within each of the experimental groups were analyzed. Prior to supplementation, all the participants had low vitamin D status.

The present study findings revealed a highly significant rise in dietary vitamin D$_3$ intake and serum vitamin D$_3$ levels (p<.001) in both the groups—Vitamin D$_3$ (E1) and Vitamin D$_3$ and VCNO (E2) supplementation groups (Table 3). This indicates the effectiveness of the administered dosage of vitamin D in improving vitamin D status of the early KOA participants who were deficient in vitamin D$_3$ before intervention.

The results were further analyzed to understand any difference between the effectiveness of the two interventions in altering the selected parameters. This analysis is presented in Figures 1, 2, 3.

Positive effects on cartilage degeneration, inflammation, and functional abilities were seen in both experimental groups (Figures 1-3). Further, to understand the level of significance in the effectiveness of the two supplementation protocols, an unpaired t-test was applied to the mean difference of pre and post-supplementation values for various parameters. The results are presented in Table 4.

Though a highly significant rise in serum 25 (OH) vitamin D was observed post-supplementation in both groups, the mean difference between the groups was not significant.

Prior to supplementation with vitamin D$_3$, progressive cartilage degeneration along with increasing severity of KOA was observed in the patients, supported by significantly higher (p<.05) mean sCOMP levels in grade II than in grade I patients. But, post-supplementation, serum CRP levels and ESR status showed highly significant reductions in participants of both genders of both the groups (t=6.471, p<.001 and t=7.614, p<.001) (Table 3). A declining trend was observed in the serum inflammatory markers, ESR and CRP, in both experimental groups (Figure 1C and 1D).
**Table 3.** Vitamin D Status of the Participants (n=100).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Gender</th>
<th>E1 (Vitamin D₃ supplementation) (n=50)</th>
<th>E2 (Vitamin D₃ +VCNO supplementation) (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Serum 25 (OH) D levels (ng/dl)</td>
<td>Males (n=25)</td>
<td>14.02 ± 3.57</td>
<td>46.04 ± 9.236</td>
</tr>
<tr>
<td></td>
<td>Females (n=25)</td>
<td>13.93 ± 3.60</td>
<td>43.67 ± 9.10</td>
</tr>
<tr>
<td>Dietary Vitamin D₃ intake (IU)</td>
<td>Males (n=25)</td>
<td>27.24 ± 22.59</td>
<td>49.15 ± 28.04</td>
</tr>
<tr>
<td></td>
<td>Females (n=25)</td>
<td>16.07 ± 14.24</td>
<td>34.62 ± 20.26</td>
</tr>
</tbody>
</table>

#Note : (**p<.01; ***p<.001); (#E1–vitamin D₃ supplementation ; E2–vitamin D₃ and VCNO supplementation).
Figure 1. Post-supplementation effects and the mean reduction of A) serum 25 (OH) D levels, B) sCOMP levels (cartilage marker), C) CRP levels (inflammatory marker), D) ESR levels (inflammatory marker) of the participants.

# E1M—Experimental Group 1 Males, E1F—Experimental Group 1 Females; E2M—Experimental Group 2 Males, E2F—Experimental Group 2 Females.
Figure 2. Mean reduction of VAS score and Total WOMAC score upon supplementation.

Figure 3. Mean improvement of distance covered during 6MWT upon supplementation.

# E1M–Experimental Group 1 Males, E1F–Experimental Group 1 Females; E2M–Experimental Group 2 Males, E2F–Experimental Group 2 Females.
**Table 4.** Mean Difference in the Effectiveness of Supplementation on Various Parameters.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Gender</th>
<th>E1 (Mean ± SD)</th>
<th>E2 (Mean ± SD)</th>
<th>t value</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum 25 (OH) D (mg/dl)</td>
<td>Male (n=25)</td>
<td>31.94 ± 5.81</td>
<td>34.77 ± 7.67</td>
<td>-1.48</td>
<td>.15</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>29.74 ± 5.78</td>
<td>32.88 ± 11.00</td>
<td>-1.26</td>
<td>.21</td>
</tr>
<tr>
<td>Serum CRP (mg/dl)</td>
<td>Male (n=25)</td>
<td>.21 ± .19</td>
<td>.40 ± .35</td>
<td>-3.25**</td>
<td>.002</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>.34 ± .26</td>
<td>.74 ± .63</td>
<td>-2.96**</td>
<td>.006</td>
</tr>
<tr>
<td>ESR (mm/hr)</td>
<td>Male (n=25)</td>
<td>15.72 ± 10.80</td>
<td>20.08 ± 12.25</td>
<td>-1.34</td>
<td>.19</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>18.52 ± 12.16</td>
<td>21.20 ± 11.27</td>
<td>-8.1</td>
<td>.22</td>
</tr>
<tr>
<td>sCOMP (pg/ml)</td>
<td>Male (n=25)</td>
<td>2191.82±1249.57</td>
<td>3170.9 ± 1837.95</td>
<td>-5.37***</td>
<td>.000</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>2447.16±1146.91</td>
<td>3744.74 ± 2108.61</td>
<td>-7.02***</td>
<td>.000</td>
</tr>
<tr>
<td>6MWT distance (m)</td>
<td>Male (n=25)</td>
<td>4.92 ± 2.60</td>
<td>28.44 ± 8.32</td>
<td>-13.49***</td>
<td>.000</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>4.60 ± 1.66</td>
<td>22.96 ± 6.43</td>
<td>-13.83***</td>
<td>.000</td>
</tr>
<tr>
<td>VAS score (mm)</td>
<td>Male (n=25)</td>
<td>17.00 ± 2.57</td>
<td>37.30 ± 5.74</td>
<td>-16.15***</td>
<td>.000</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>16.61 ± 4.79</td>
<td>37.64 ± 7.05</td>
<td>-12.35***</td>
<td>.000</td>
</tr>
<tr>
<td>Total WOMAC score</td>
<td>Male (n=25)</td>
<td>8.48 ± 22.23</td>
<td>23.12 ± 8.70</td>
<td>-9.61***</td>
<td>.000</td>
</tr>
<tr>
<td></td>
<td>Female (n=25)</td>
<td>46.80 ± 15.45</td>
<td>24.52 ± 11.95</td>
<td>-8.46***</td>
<td>.000</td>
</tr>
</tbody>
</table>

# Note: (***p<.001; **p<.01); (#E1, vitamin D₃ supplementation ; E2 vitamin D₃ and VCNO supplementation).

sCOMP (<.001), ESR, and serum CRP (<.001) reduced significantly in both the groups, indicating a decline in cartilage degeneration and inflammatory status. However, the reduction in the ESR and CRP was lower with vitamin D₃ supplementation alone than with vitamin D₃ and VCNO supplementation. Similarly, a higher reduction in mean sCOMP levels was observed with the double supplementation received by experimental group 2 (Figure 1B).

VAS score (<.001) significantly reduced in both groups, indicating reduced self-perceived pain intensity. Improvements in functional abilities and pain (as indicated by the increased 6-MWT and reduced VAS and Total WOMAC scores) were higher with vitamin D₃ and VCNO supplementation than with vitamin D₃ supplementation alone (Figures 2-3).

The results presented in Table-3 revealed a significant improvement in distance covered during the 6MWT (p<.001), and a significant reduction in VAS score (p<.001) and total WOMAC score (p<.001) in both the experimental groups, with the improvement being higher in E2,
indicating a synergistic effect between vitamin D₃ and VCNO on pain and functional abilities in early KOA patients. Interestingly, the mean distance covered during 6-MWT was higher and mean Total WOMAC score was lower in male participants compared to female participants in both groups. Total WOMAC score (p<.001) significantly reduced, with a highly significant improvement in the distance covered during the 6 MWT (<.001) more in female participants than in male in both the experimental groups indicating improved functional abilities.

Vitamin D₃ and VCNO supplementation also showed a positive effect on all the parameters studied including serum CRP (p<.001), sCOMP (p<.001), VAS score (p<.001), total WOMAC (p<.001), and 6 MWT distance (p<.001) for both the genders. But the effect on serum vitamin D levels and ESR was not significant (Table 3). The mean difference of effect in all the above parameters was higher in the vitamin D₃ and VCNO supplementation group (E2) than the group which received vitamin D₃ alone (E1).

**DISCUSSION**

**Vitamin D Supplementation in Early KOA:** Vitamin D supplementation improved the distance covered during the 6MWT and WOMAC score, and reduced VAS score with an improvement in serum vitamin D levels in early KOA [32]. The administered doses of calciferol (bolus dose of 60,000 IU/day for 10 days, followed by 6,000 IU/month for six months) have been reported to reduce pain and improve WOMAC score, demonstrating the clinical benefit of vitamin D₃ supplementation in early KOA patients [33]. A meta-analysis of 4 randomized control trials revealed that daily vitamin D supplementation of more than 2000 IU in early KOA patients significantly improved pain and function scores but not tibial cartilage loss and incidence of adverse events [34]. These researchers advocated a need for more research studies with higher doses and unique combination of forms to support the role of vitamin D supplementation in attenuating KOA advancement.

**VCNO supplementation in bone health:** Researchers have reported several health benefits of VCNO such as a role in weight management through the reduction of visceral adiposity (since its SFA content is majorly composed of lauric acid (48%-56%) and it is a rich source of MCTs [35, 36, 37]. Also, the antioxidant polyphenol fraction of VCNO reduces the oxidative stress in chronic diseases [38, 39]. Researchers have confirmed the role of VCNO in reducing bone loss and osteoporosis progression in rats, but its efficacy in human bone health still needs to be tested [40, 41]. VCNO, being rich in polyphenols and medium-chain fatty acids, acted as an anti-stress functional oil at the dose of 10 ml/kg-body-weight in mice, reducing immobility time, restoring oxidative stress post-force-swim test, raising brain antioxidant levels, decreasing brain 5-hydroxytryptamine levels, decreasing the weight of the adrenal glands, and lowering serum cholesterol, triglyceride, glucose, and corticosterone levels [42]. VCNO supplementation also improved the functional status and QOL of cancer patients [43]. However, all these studies were based on rat models, the information on the effect of VCNO on functional abilities in bone health of humans is not available so far. Hence, this present study could be considered as the first attempt to ascertain the effect of VCNO on pain and functional abilities of KOA patients.
**Effect of Vitamin D and VCNO Supplementation on Vitamin D Status, Cartilage Degeneration, Inflammation and Functional Abilities in Early KOA Management:** KOA is a chronic degenerative joint disease. Its pathophysiology is initiated with cartilage degeneration in the knee joints. Low vitamin D status increases the risk for OA, resulting in reduced cartilage volume. The role of active vitamin D in reducing articular cartilage degeneration by triggering chondrocyte hypertrophy has been proven [44]. Recent research reported that vitamin D supplementation significantly improved serum 25(OH)D levels, PTH, severity grade, and pain score of Indian OA patients who previously had low vitamin D status [45]. The present study on early KOA Indian patients confirmed these findings indicating a positive effect of Vitamin D supplementation in the management of KOA. Though the role of vitamin D3 in bone health is well established, it’s anti-inflammatory effect needs to be further explored.

Recently, in KOA pathophysiology research, the focus has been shifted from mere cartilage degeneration towards the concept of a whole joint disease, with due emphasis on the chronic inflammation triggered by the metabolic alterations secondary to synovitis in the knee joint [46]. VCNO’s anti-arthritis effect has been reported in arthritis induced rats. This effect is due to the bioactive compounds (i.e., the polyphenol fraction isolated from VCNO) which exhibited antioxidant and anti-inflammatory effects [47]. Researchers have reported the anti-inflammatory effects of vitamin D3 as well as the anti-inflammatory and analgesic effects of VCNO but have indicated a strong need for more evidence based research on these within the frame of OA management [48, 49]. sCOMP levels serve as a prognostic biomarker of cartilage degeneration in KOA at earlier stages and they are directly proportional to cartilage degeneration [50]. Vitamin D3 supplementation in healthy women was effective in maintaining lower CRP levels [51]. KOA is a chronic form of arthritis, wherein afflicted individuals experience pain and stiffness in the knee joints, affecting daily function, which impacts their quality of life. Hence, supplementation was also assessed for its effect on self-perceived pain (VAS score), stiffness, and functional abilities (WOMAC score and 6-MWT). Supplementation was found to have a positive impact through a coincidence with declining trend in pain intensity and significant improvements in functional abilities. The findings of the present study confirmed this declining trend in cartilage degeneration and inflammatory markers as well as improvement in functional abilities in early KOA patients, post intervention. It also revealed the improved effectiveness of vitamin D3 and VCNO supplementation in reducing inflammation and thereby, cartilage degeneration, indicating an anti-inflammatory and anti-arthritic effect. Based on the above results, the null hypothesis proposed by the investigators that the intake of VCNO & Vitamin D does not offer any cumulative benefits to early KOA patients has been rejected.

**CONCLUSION**

Vitamin D3 and VCNO supplementation could be a beneficial strategy in delaying KOA progression by improving vitamin D status; reducing cartilage degeneration, inflammation and pain; and improving functional abilities. Simultaneous improvement of vitamin D3 status and reduction of cartilage degeneration, inflammation and oxidative stress should be considered crucial to early KOA management. Non-conventional antioxidant and anti-inflammatory nutrients and functional foods such as vitamin D3 and VCNO could be further explored.
List of Abbreviations: KOA, Knee Osteoarthritis; KL grading, Kellgren Lawrence grading; VCNO, Virgin Coconut oil; serum 25 (OH) D; serum 25 – hydroxy D; sCOMP, serum cartilage oligomeric matrix protein; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS visual analogue scale, WOMAC Western Ontario Mcmasters osteoarthritis index; ELISA, Enzyme linked Immunosorbent Assay; 6-MWT, six minute walk test; QOL, Quality of life.

Competing Interests: There are no conflicts of interest to declare.

Author’s Contributions: This work is a part of a PhD research project of Monal Velangi. The execution of the study, data collection, statistical analysis and manuscript preparation were all done by her. Subhadra Mandalika, who served in the capacity of research guide, provided guidance for the project documentation. Surendra Shukla, as the Orthopaedic surgeon, provided medical expertise in disease diagnosis. Vandana Pradhan, as the expert Scientist in Clinical Immunology, helped in the sCOMP analysis at NIIH.

Acknowledgements and Funding: This research was partly supported by a scholarship from Women Graduates Union, International Federation of Women.

REFERENCES


